Levi & Korsinsky, LLP announces that a ACAD class action lawsuit has been filed on behalf of investors who purchased Acadia Pharmaceuticals Inc. (ACAD) securities between June 15, 2020 and April 4, 2021. For more on the ACAD Lawsuit please contact us today.
According to the Acadia Pharmaceuticals Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Acadia Pharmaceuticals Inc. you have until June 21, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.